Natural Investments LLC Acquires New Stake in Haleon plc (NYSE:HLN)

Natural Investments LLC bought a new position in shares of Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 88,100 shares of the company's stock, valued at approximately $840,000.

Several other institutional investors have also recently made changes to their positions in the stock. Addison Advisors LLC raised its position in shares of Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after buying an additional 1,106 shares in the last quarter. Synovus Financial Corp increased its holdings in shares of Haleon by 0.8% in the third quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock worth $1,575,000 after buying an additional 1,216 shares during the period. Greenleaf Trust increased its holdings in shares of Haleon by 8.4% in the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company's stock worth $164,000 after buying an additional 1,333 shares during the period. Baron Wealth Management LLC increased its holdings in shares of Haleon by 4.3% in the fourth quarter. Baron Wealth Management LLC now owns 33,632 shares of the company's stock worth $321,000 after buying an additional 1,381 shares during the period. Finally, Peapack Gladstone Financial Corp increased its holdings in shares of Haleon by 3.2% in the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company's stock worth $474,000 after buying an additional 1,390 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

HLN has been the topic of several analyst reports. Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. HSBC reaffirmed a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Haleon has an average rating of "Hold" and a consensus price target of $10.95.

Remove Ads

Haleon Price Performance

Shares of HLN opened at $10.40 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market cap of $47.06 billion, a PE ratio of 30.57, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The firm has a fifty day simple moving average of $9.69 and a two-hundred day simple moving average of $9.87.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. On average, equities analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is an increase from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio is currently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.